OR WAIT null SECS
July 01, 2015
Bill Hartzel, Director Strategic Execution, Advanced Delivery Technologies at Catalent Pharma Solutions, spoke with BioPharm International about blow-fill-seal for aseptic processes.
Gordon Haines, Chief Executive Officer, and Kay Thiele, Head of Product Optimization, at Rottendorf Pharmaceuticals, spoke with BioPharm International about the human element in pharmaceutical manufacturing.
Brady Cole, VP of Commercial Operations, at ABEC, spoke with BioPharm International about biopharmaceutical manufacturing processes.
Barry Holtz, Principal, at Holtz Biopharma Consulting, and Klyo Collaborative, spoke with BioPharm International about collaborative success strategies for biopharm companies.
May 30, 2013
Rita Peters, Editorial Director for Pharmaceutical Technology and BioPharm Inernational talks with Ferdinand Dabu, director of marketing at SGS live at Interphex 2013 about extractables and leachables. In this interview they discuss special considerations for testing for extractables and leachables for both small molecule and biological drug development.
Rita Peters, Editorial Director for Pharmaceutical Technology and BioPharm Inernational talks with Ferdinand Dabu, director of marketing at SGS live at Interphex 2013 about extractables and leachables. In this interview they discuss the key elements of an effective testing program to identify extractables from materials and leachables in drug products.
Rita Peters, Editorial Director for Pharmaceutical Technology and BioPharm Inernational talks with Ferdinand Dabu, director of marketing at SGS live at Interphex 2013 about extractables and leachables. In this interview they discuss new analytical testing procedures and instruments that are facilitating the testing processes or improving results.
Editorial Director Rita Peters interviews Alan Fisher of Dycem about risk management is applied to contamination control for pharmaceutical manufacturing
May 23, 2013
Editorial Director Rita Peters talks to with Ferdinand Dabu Director of Marketing at SGS live at Interphex
February 29, 2012
During this podcast, we will discuss the causes and implications of Adventitious Agent Contamination for pharmaceutical and biopharmaceutical manufacturers. We will discuss ways in which Lancaster Laboratories is helping manufacturers minimize the risk for this contamination to avoid production delays.